Abstract
Introduction
The hygiene hypothesis and variants such as the microbial deprivation, old friend mechanism, and biodiversity hypotheses are based on epidemiological observations which have demonstrated an inverse relationship between the prevalence of allergicautoimmune diseases and exposure to environmental microbes, such as endemic parasites. 1, 2 Specifically, it has been suggested that as an unanticipated consequence of improved public hygiene, diminished exposure to evolutionarily normal microbiota in industrialized countries may adversely affect immunoregulation and therefore predispose to immunopathology. [3] [4] [5] [6] [7] In animal models and clinical trials, live microbes, purified microbial products, and microbial-based cellular immunotherapeutics have been administered in an effort to ameliorate allergy or autoimmunity. [8] [9] [10] [11] [12] [13] The effects of anti-helminth deworming programs on allergy, autoimmunity, and immune function have varied in different studies. [14] [15] [16] In the case of multiple sclerosis (MS), a report by Leibowitz et al. 17 in 1966 first suggested that high levels of sanitation were associated with the risk of developing this disease, a finding confirmed by subsequent epidemiological surveys. 18 Additionally, an observational study in patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated dramatic clinical, immunological, and neuroimaging improvements in patients who had been naturally infected with human helminth parasites in the field. 19, 20 Exploratory 1a clinical trials of helminth therapy in MS have been inconclusive, likely because of small sample size and other study design limitations. [21] [22] [23] In order to assess the effects of helminth therapy in MS, live ova of the porcine whipworm, Trichuris suis (TSO), were administered orally to 16 disease-modifying treatment (DMT) naive RRMS subjects for 10 months in the phase 1b HINT 2 (HelminthInduced Immunomodulation Therapy) clinical trial. HINT 2 is the first prospective hygiene hypothesisbased clinical trial in MS or any neurological disease which has employed contrast-enhanced magnetic resonance imaging (MRI) endpoints as recommended for exploratory trials in MS, 24 subjects with early disease and without confounding DMT exposure, baseline versus treatment (BVT) control design, and treatment of sufficient duration to assess the possibility of late adverse events (AEs) or benefits.
Materials and methods

Study design
A BVT design was employed, in which each subject served as their own longitudinal control. BVT study design has been preferred for most phase 1 investigations of putative MS treatments, as statistical power in BVT design is achieved with fewer subjects than parallel groups (PG) design. 24, 25 HINT 2 was divided into periods for screening (1 month), observation without treatment (4 months), TSO treatment (10 months), and post-treatment observation (4 months) ( Figure 1) . Specifically, the 10-month treatment period was chosen in order to assess any possible AE or treatment effect only apparent during chronic TSO administration. The primary outcome measures were safety, as determined by the incidence of AE, and change in MS activity, as judged by the total number of gadoliniumenhancing (GdE) lesions observed on masked readings for (a) five brain MRIs obtained during the screening-observation phases of the trial compared to (b) five brain MRI scans obtained during the last months of treatment ( T. suis ova production, testing, and administration TSO was purchased from Ovamed, Hamburg, Germany (lot number 9009102901) where it was certified at Good Manufacturing Practice (GMP) pharmaceutical standards of purity and sterility. Details of post-production storage, testing for adventitious agents, and ova stability are presented in Supplementary Material. Based on previous studies, 21, [26] [27] [28] GMP TSO was administered to subjects at a dose of 2500 viable ova orally every 2 weeks.
Subjects and ethical statement
Subjects were recruited if they met the criteria of the McDonald Committee for RRMS, 29 had a confirmed diagnosis within 3 years of study entry, had never received DMT prior to the study and were willing to 31 was performed by a certified technician; subsequently, these assessments were reviewed and an unmasked interim history and physical examination were performed by a treating neurologist. These assessments were also performed at unscheduled clinic visits for AEs or possible relapse. Routine laboratory assessments, including a complete blood count, liver and renal function tests, stool ova and parasite determination, and pregnancy tests in female subjects were performed at the University of Wisconsin Hospital and Clinics clinical laboratory per the schedule indicated in Figure 1 . Enzyme-linked immunosorbent assays (ELISA) specific for antibodies to T. suis and flow cytometric assays for cell phenotype were performed as previously described. 21 Colonoscopies with mucosal biopsies were performed in selected subjects. In all cases, the primary indication for colonoscopy was routine colorectal cancer screening; additionally, secondary informed consent was obtained for two to five research biopsies of colonic mucosa. Mucosal samples were fixed in formalin, embedded in paraffin, and stained with hematoxylin and eosin. Safety was assessed by application of Food and Drug Administration (FDA)-Center for Biologics Evaluation and Research (CBER) criteria, modified as indicated in Supplementary Material and graded as follows: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life-threatening; and Grade 5, death.
MRI assessments
Brain MRIs were performed with and without intravenous contrast (double-dose gadolinium, O.2 mmol/ kg body weight) on a 3-Tesla scanner (GE Healthcare, Waukesha, WI, at the University of Wisconsin site and a Siemens Healthineers, Malvern, PA, at the Marshfield Clinic site) at the time points indicated in Figure 1 . For masked readings of each subject's MRI, all identifying information was removed and replaced by a code number, after which the scans were presented in random (not chronological) order to three board-certified neuroradiology fellows who counted the number of GdE. Following the initial reading, the coded images were reviewed by the masked attending neuroradiologist, who resolved any discrepancies or errors during the first reading. Subsequently, the MRI data were locked, and the images were reassembled in chronological order for tabulation of GdE. Details of the MRI sequences for HINT 2 are provided in Supplementary Material.
Statistical assessments
A primary outcome measure of HINT 2 was the mean number of total GdE when observation and treatment MRIs for the study cohort were assessed in a Poisson regression model with a robust variance estimator. Eosinophilia, humoral responses to T. suis, and T regulatory enumerations were analyzed by one-way analysis of variance (ANOVA; GraphPad PRISM version 6.0). EDSS and MSFC values were evaluated by unpaired t-test (GraphPad PRISM version 6.0). The safety analysis was descriptive rather than inferential, with AEs listed by symptom or disease and frequency without formal statistical analysis for significance. In this phase 1b investigation, all study analyses included all subjects, regardless of adherence to the study protocol.
Results
The demographic characteristics of our subjects are indicated in Table 1 . In general, HINT 2 subjects were relatively young, and their RRMS was of short duration and mild disability.
Safety
No serious AE (grade 3 and above) were noted during this study. Similar to prior TSO clinical trials, including the HINT 1 MS study, 21 the phase 1a MS study of Voldsgaard et al., 23 and the allergic rhinitis study of Bager et al., 28 no significant, treatment-related AE were noted in any system, except for the gastrointestinal system, where grade 1 or 2 AE occurred in 9 of the 16 subjects (Table 2) . Grade 1 gastrointestinal AE, such as diarrhea, mild abdominal pain, and flatulence, occurred in six subjects, with onset at approximately 30-40 days after the first TSO dose, followed by spontaneous remission in several days. We hypothesize that these symptoms may represent a robust innate immune response during the first encounter with maturing T. suis larvae. Subject number 212 experienced moderate diarrhea (grade 2) with spontaneous resolution in 7 days. Two exceptional subjects, numbers 110 and 111, had grade 2 gastrointestinal symptoms which persisted for several weeks and required a clinic visit for assessment and symptomatic treatment, followed by complete remission of symptoms. In no subject did gastrointestinal symptoms interfere with school or work activities.
Clinically indicated colonoscopies were performed on one healthy control subject, two MS control subjects not receiving TSO, and two HINT 2 MS subjects (study numbers 122 and 125) at month T 10 of their TSO treatment. As expected for patients undergoing routine cancer screening, the colonoscopy cohort (mean age 44.6 years, 4/5 female subjects) was older than the general HINT 2 cohort. Apart from benign polyps, no histological abnormalities were observed on hematoxylin-eosin-stained colonic mucosal biopsies in any subject, including those treated with TSO ( Figure 2 ). Prior to the investigations, it was not known whether ingestion of the polyethylene glycol (PEG) colonic preparation solution would dislodge T. suis larvae from the colonic epithelium; for this reason and in order to maintain any putative therapeutic TSO effect at month T 10 , the colonoscopies on the two MS-TSO subjects were delayed until approximately 3-4 weeks after the last day of ova administration during month T 10 . In colonoscopies performed on the two subjects who had received TSO, robust, live larvae were observed in subject 122 (Figure 2 ) but not in subject 125; it is not clear whether the difference in larval detection was due to PEG preparation, colonoscopy timing, or other factors. No AE beyond transient, expected discomfort and sedation were encountered during or following colonoscopies.
No neurological AE were noted during clinical assessments and MRI over-reads in real time, apart from typical MS symptoms, signs, and lesions. There were seven relapses of MS during the study: two relapses occurred before TSO treatment, two during TSO treatment, and three after TSO treatment (Table 2) ; one subject required corticosteroid treatment during their relapse. After relapse, all subjects regained baseline function. Apart from transient and reversible alterations in the masked assessments during relapses noted above, there was no significant change in clinical disability during a All gastrointestinal symptoms were considered TSO treatment-related. The duration of symptoms was 1 week or less in seven subjects. In subject 110, grade 2 symptoms were intermittent for 30 days; and in subject 111, grade 2 symptoms were intermittent or recurrent for 75 days. b Non-gastrointestinal symptoms were all grade 1, transient, and were considered not clearly related to TSO treatment. c A relapse was defined as new symptoms noted by the subject, in the absence of fever, infection, or other factor contributing to a pseudoattack, in the presence of objective signs on neurological examination corresponding to the new symptoms, with a duration of 24 hours or greater, and an increase in EDSS of at least one point in the total scale or two points in the relevant functional system subscale. Relapses by subject number and study month of relapse were: observation (subjects 118, O4; 216, O4), treatment (subjects 212, T1; 118, T8), and post-treatment (subjects 115, P1; 218, P2; 125, P4). d Missing MRI scans: in total, per protocol, 176 brain MRIs with contrast were planned. In the table, the number of missing scans is shown in the numerator and the planned scans in the denominator for each study period. The most common reasons for a missed scan were failure to obtain IV access, subject transportation, and MRI machine non-operative. In HINT 2 all study data, including MRI scans, were included for all subjects, regardless of adherence to protocol.
the clinical trial; for example, the EDSS mean and standard deviation was 1.3 ± 0.9 at study entry (month S 1 ) and 1.1 ± 1.3 at the last treatment visit (month T 10 ) (non-significant difference, t-test). The corresponding MSFC values were 0.52 ± 0.34 at month S 1 and 0.86 ± 0.28 at month T 10 (p-value 0.007, t-test). These results likely reflect the demographics of our study participants, who had declined conventional DMT, were relatively young, and whose MS was non-disabling and of short duration.
Laboratory and immunological assessments
At the indicated laboratory time points (Figure 1 ), no abnormality was noted in any subject during assessment of complete blood count, liver and renal function, and pregnancy screening, except for increased blood eosinophils and positive T. suis serology during TSO treatment ( Figure 3 ). All subjects had evidence of T. suis infection as manifest by at least a twofold increase in blood eosinophils relative to baseline and/or specific antibody for T. suis. Interestingly, the peak in blood eosinophils was most prominent during the initial stages of TSO treatment, corresponding to the period in which gastrointestinal symptoms were most common, while the peak of antibody response to T. suis occurred at month T 10 of treatment. Ova or parasites were not detected in any stool sample. An increase in peripheral blood lymphocytes with T regulatory phenotype (FOXP3 + , CD25 + , CD127 -, CD4 + ) occurred during treatment and extended into the post-treatment observation period (Figure 4) .
MRI assessments
For the entire cohort, the mean number of GdE per MRI scan during the observation period was 3.25; during the treatment period, the mean number of GdE per MRI scan was 2.10. The relative reduction in the group MRI activity when the observation period was compared to the treatment period was 35%; however, this trend failed to meet statistical significance for the study primary endpoint (p-value 0.08). Additionally, since in the BVT design of HINT 2 each subject served as his or her control, we also analyzed the MRI changes for each subject for BVT. As expected, there was wide variability in MRI activity at the level of individuals ( Figure 5 ). Although the magnitude of change, expressed as the observation-treatment difference in mean number of GdE per MRI scan, was small in many subjects, 12 of 16 subjects experienced an absolute diminution of GdE during TSO treatment.
Discussion
During the HINT 2 clinical trial, live ova from the porcine whipworm, T. suis, were administered to 16 Colonic biopsy demonstrating to T. suis larvae in cross section (stars), normal-appearing colonic crypt (straight arrow), and normal-appearing lamina propria (curved arrow) (×100). The anterior end of the worm has burrowed into the superficial epithelium near the crest of the colonic crypt and is covered by a thin layer consisting of the apical surfaces of epithelial cells. 32 These photographs have not been published previously but were taken from the same subject reported on previously, 8 with permission (Wiley). RRMS subjects in order to assess the safety of this agent and its effects on clinical and MRI outcomes. Following oral administration of TSO, larvae hatched and established a transient infection of the superficial colonic mucosa in these subjects. This is consistent with prior experimental studies of whipworms in animals and humans. [32] [33] [34] Since T. suis is not a human pathogen and does not establish a persistent colonization or produce progeny worms in the human host, it was necessary to administer ova every 2 weeks during the treatment period in order to maintain continuous larval whipworm infection of subjects' colonic mucosa.
There were three principal findings in our study. First, T. suis larvae were able to efficiently colonize the colonic mucosa, as evidenced by serum antibody responses to T. suis and/or increased eosinophil counts in all subjects. Second, administration of TSO was safe in RRMS subjects, as evidenced by the absence of serious clinical AE, stable neurological function, lack of laboratory evidence of systemic toxicity, and normal colonic histology. In terms of tolerability, transient gastrointestinal symptoms occurred in 9 of the 16 subjects, usually shortly after treatment initiation; however, these symptoms were not of sufficient intensity or duration to interfere with activities of daily living such as school or work. Third, serial neuroimaging studies of the cohort demonstrated a trend for a 35% relative decrease (p-value = 0.08) in the mean number of GdE per scan when MRI results before and during TSO treatment were compared. Additionally, since HINT 2 was based on a BVT design, in which each subject served as his or her own control, the MRI data were also analyzed at the level of each individual's experience, that is, the difference in MRI activity for a given subject when baseline assessments were compared to treatment assessments. This analysis showed diminution or stability in mean GdE in 12 of 16 subjects during treatment. Currently, it is not known whether the observed individual differences in MRI activity were due to subject-specific responses to TSO, variability in individual MS natural histories, or chance.
HINT 2 did not demonstrate the very dramatic clinical and MRI improvements in RRMS activity found during an observational study of pathogenic human helminth infections of MS patients in the field; 19 nor did HINT 2 confirm results of an exploratory phase 1a clinical trial of TSO treatment in RRMS which showed no signals of clinical or immunological benefit. 23 The disparities between HINT 2 and previous studies may reflect differences in study design between observational investigations and BVTcontrolled clinical trials, numbers or types of subjects, confounding effects of concurrent DMT in some studies, duration of helminth infection, MRI methodology, different biologies of porcine and human helminths, differential epigenetic programming in subjects raised in regions with and without endemic parasitism, 35 and other factors. 13, 14, 36 There are several limitations to our study. First, the demographic features of the HINT 2 subjects with early RRMS may have limited our ability to detect (2) treatment period (the set of five scans for months T 6 , T 7 , T 8 , T 9 , T 10 ). Subsequently, the difference between mean GdE at baseline and mean GdE during treatment (BVT difference) was determined for each subject. Determinations for each individual are indicated by a dot and are expressed such that a positive BVT difference indicates worsening (i.e. more GdE during treatment) and a negative BVT difference value indicates improvement (i.e. less GdE during treatment). Each dot represents the data from 10 MRI scans for an individual, as designated by color and subject number in the key.
substantial changes in clinical or MRI outcomes after TSO treatment. Second, while the critically important considerations of the dose, frequency, and duration of TSO treatment were based on the best animal and human experimental data available at the time of study design reviewed in Fleming and Weinstock, 8 Summers et al., 26 and Bundy and Cooper, 34 we cannot be certain that the conditions of TSO administration were in fact optimal. In several recent clinical trials for inflammatory bowel disease, for example, TSO has been administered at single or repeated doses of 7500 ova without serious AE. 8, 37 Third, it is possible that our MRI results represent regression to the mean. Nevertheless, we believe that regression to the mean during HINT 2 is unlikely since findings of the Miller Taskforce 24 and experience with subjects receiving placebo during similar RRMS exploratory trials at our centers suggest that regression to the mean is likely to be minimal or absent when the observation run in period is at least 4-6 months. Additionally, limited post-treatment MRI scans (1-2 studies per subject) showed either no change or an increase in GdE in 9 of 16 subjects (data not shown), suggestive of either stability or mild rebound after TSO cessation in many subjects, rather than continued regression toward a hypothetical natural mean. Fourth, the primary outcome measure, reduction in GdE for basement versus treatment for the cohort (p = 0.08), did not reach the conventional standard for statistical significance (p ⩽ 0.05). However, consideration of the totality of our findings nonetheless suggests that there is a genuine but modest trend supporting positive effects of TSO; these findings include the preponderance of favorable MRI responses at the level of individual subjects ( Figure 5 ), an increase in peripheral blood lymphocytes with a T regulatory phenotype (Figure 4(b) , p ⩽ 0.0001), evidence of a modified Th2 immune response, and favorable changes in stool microbiota (manuscript in preparation).
In conclusion, the results of the HINT 2 clinical trial, in contrast to earlier, smaller exploratory studies, suggest that TSO treatment may be associated with a trend for protective neuroimaging and immunological outcomes, although these effects were of modest degree and varied considerably among individual subjects. On the other hand, the findings of HINT 2 also indicate that a dramatic improvement of MS, as reported in prior observational studies of natural helminth infection in the field, is highly unlikely, at least for TSO at the doses currently employed. Certainly, we agree with McKay that every "parasite survives at some cost to the health and/or nutritional status of the host"; 38 
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